GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medite Cancer Diagnostics Inc (OTCPK:MDIT) » Definitions » 12-1 Month Momentum %

MDIT (Medite Cancer Diagnostics) 12-1 Month Momentum % : N/A% (As of Sep. 21, 2024)


View and export this data going back to . Start your Free Trial

What is Medite Cancer Diagnostics 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-09-21), Medite Cancer Diagnostics's 12-1 Month Momentum % is N/A%.

The industry rank for Medite Cancer Diagnostics's 12-1 Month Momentum % or its related term are showing as below:

MDIT's 12-1 Month Momentum % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -15.03
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Competitive Comparison of Medite Cancer Diagnostics's 12-1 Month Momentum %

For the Medical Instruments & Supplies subindustry, Medite Cancer Diagnostics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medite Cancer Diagnostics's 12-1 Month Momentum % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medite Cancer Diagnostics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Medite Cancer Diagnostics's 12-1 Month Momentum % falls into.



Medite Cancer Diagnostics  (OTCPK:MDIT) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medite Cancer Diagnostics  (OTCPK:MDIT) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Medite Cancer Diagnostics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Medite Cancer Diagnostics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Medite Cancer Diagnostics Business Description

Traded in Other Exchanges
N/A
Address
4203 SouthWest 34th Street, Orlando, FL, USA, 32811
Medite Cancer Diagnostics Inc is a US-based company which specializes in the marketing and selling of MEDITE core products (instruments and consumables), manufacturing, development of new solutions in histology and cytology and marketing of molecular biomarkers. The company manufactures medical devices and consumables are for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. Medite operates through the single segment for cancer diagnostics instruments and consumables for histology and cytology laboratories. It offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis.
Executives
Lewis William Austin Iv director, 10 percent owner 201 E 87TH STREET, APT 5H, NEW YORK NY 10128
John H Abeles director 2365 NW 41ST STREET BOCA RATON FL 33431
Joel S Kanter director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Clinton Severson director C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587

Medite Cancer Diagnostics Headlines

No Headlines